Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $101.80 USD
Change Today -0.79 / -0.77%
Volume 458.1K
GEVA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:36 PM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

synageva biopharma corp (GEVA) Snapshot

Open
$103.02
Previous Close
$102.59
Day High
$110.00
Day Low
$96.72
52 Week High
01/26/15 - $122.88
52 Week Low
09/22/14 - $60.19
Market Cap
3.8B
Average Volume 10 Days
274.4K
EPS TTM
$-5.87
Shares Outstanding
37.0M
EX-Date
12/30/08
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNAGEVA BIOPHARMA CORP (GEVA)

synageva biopharma corp (GEVA) Related Bloomberg News

View More Bloomberg News

synageva biopharma corp (GEVA) Related Businessweek News

No Related Businessweek News Found

synageva biopharma corp (GEVA) Details

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL) under the Kanuma brand name for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy in a Phase 1/2 study for lysosomal storage disease, known as mucopolysaccharidosis type IIIB; SBC-105, an enzyme replacement therapy in preclinical development for rare disorders of calcification; and other programs. The company was founded in 1996 and is headquartered in Lexington, Massachusetts.

282 Employees
Last Reported Date: 02/26/15
Founded in 1996

synageva biopharma corp (GEVA) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $601.1K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $360.5K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $380.1K
Executive Vice President of Global Medical an...
Total Annual Compensation: $379.6K
Senior Vice President of JAPAC & LATAM Commer...
Total Annual Compensation: $378.8K
Compensation as of Fiscal Year 2013.

synageva biopharma corp (GEVA) Key Developments

Synageva BioPharma Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Mexico

Synageva BioPharma Corp. announced the submission to the Comisin Federal para la Proteccin contra Riesgos Sanitarios (Cofepris) in Mexico for Kanuma as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency), a rare genetic disease with significant morbidity and early mortality. The submission to Cofepris for Kanuma included previously reported data from the global, randomized, double-blind, placebo controlled Phase 3 trial in children and adults with LAL Deficiency, and the Phase 2/3 trial of Kanuma in infants with LAL Deficiency.

Synageva Biopharma Corp. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides R&D Expense Guidance for the Full Year of 2015

Synageva BioPharma Corp. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $1,237,000 compared with $3,474,000 for the same period a year ago. Loss from operations was $57,306,000 compared with $30,944,000 for the same period a year ago. Loss before provision from income taxes was $57,175,000 compared with $30,688,000 for the same period a year ago. Net loss was $57,665,000 or $1.73 per basic and diluted share compared with $30,736,000 or $1.00 per basic and diluted share for the same period a year ago. For the year, the company reported total revenues of $6,492,000 compared with $13,374,000 for the same period a year ago. Loss from operations was $192,133,000 compared with $95,903,000 for the same period a year ago. Loss before provision from income taxes was $192,108,000 compared with $95,402,000 for the same period a year ago. Net loss was $192,648,000 or $5.89 per basic and diluted share compared with $95,450,000 or $3.40 per basic and diluted share for the same period a year ago. For the full year 2015, the company expects GAAP total operating expenses between $280 million and $295 million. For the total operating expense for 2015, the company expects approximately 70% of the investment is going towards R&D that includes ongoing studies and regulatory submissions for Kanuma, clinical trials with its second program SBC-103, drug supply for lead and pipeline programs and advancement of additional pipeline programs.

FDA Accepts BLA Filing for Synageva's Kanuma™ (Sebelipase Alfa)

Synageva BioPharma Corp. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Kanuma (sebelipase alfa) for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The FDA granted the company's request for Priority Review, which shortens the regulatory review period and is reserved for investigational therapies that treat serious conditions and, if approved, would provide a significant improvement in safety or effectiveness compared to available therapies. The FDA established a target action date of September 8, 2015 under the Prescription Drug User Fee Act (PDUFA). The BLA for Kanuma included previously reported data from the global, randomized, double-blind, placebo controlled Phase 3 trial in children and adults with LAL Deficiency, and the Phase 2/3 trial of Kanuma in infants with LAL Deficiency. Patients in these trials, combined with patients in other ongoing clinical trials with Kanuma, represent the large patient population studied to date for this rare, devastating disease. LAL Deficiency is a serious and life-threatening disease that can be diagnosed with a simple blood test. LAL Deficiency causes progressive and multisystemic organ damage including cirrhosis and accelerated atherosclerosis that can lead to sudden and unpredictable clinical complications. LAL Deficiency often manifests in childhood but can be diagnosed at all ages. LAL Deficiency is caused by genetic mutations that result in decreased LAL enzyme activity in the lysosomes across multiple body tissues, leading to the buildup of fatty material in the liver, blood vessel walls and other tissues.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEVA:US $101.96 USD -0.63

GEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GEVA.
View Industry Companies
 

Industry Analysis

GEVA

Industry Average

Valuation GEVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 555.9x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 548.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNAGEVA BIOPHARMA CORP, please visit www.synageva.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.